Established in 2005 and listed on the Science and Technology Innovation Board of Shanghai Stock Exchange (stock code:
688393, stock abbreviation: LBP) on August 20th, 2020, Guangzhou LBP Medicine Science & Technology Co., Ltd. ( "LBP" for
short ) is the first listed company in the field of pathological diagnosis in China. Headquartered in Science City, LBP owns a
newly-built industrial park of nearly 30,000 m2
and is mainly engaged in the research and development, production, sales and
service of in vitro diagnostic reagents and instruments.
Since its establishment, it has been focusing on the main business with intensive cultivation and has set up a diversified technology platform and developed a number of core technologies independently, such as sedimentation liquid-based cytology, reverse
dot hybridization PCR preparation, real-time fluorescence PCR preparation, FISH probe labeling, IHC pathological diagnosis
antibody screening and quality control technologies and related supporting instrument manufacturing technologies. It is one of
the manufacturers with the most complete product lines and the most abundant varieties in the field of pathological diagnosis
in China, which can meet the needs of medical institutions at different levels. The products have passed the CE certification, BSI
certification, ISO13485 certification and the quality certification of the Ministry of Health, Labour and Welfare of Japan.
Over the years, LBP has participated in a number of national major projects in the "863 Program" and provincial and municipal
projects, obtained 61 authorized patents, including 15 patents for invention, formed 29 related software copyrights, and
possessed more than 500 registered/filed products, which are constantly increasing. Our products have covered more than
1,800 medical institutions nationwide by the synergistic advantages of self-owned brand reagents and instruments, complete
marketing network and high-quality service system.
Adhering to the enterprise tenet of "creating value for society and customers to realize the value of employees and enterprise",
LBP focuses on the business development of in vitro diagnosis, especially pathological diagnosis products related to tumor
diseases, promotes R&D innovation and the industrialization of technological achievements vigorously, strengthens the
construction of a multi-level marketing network, builds an innovative business model of online and offline integrated with vitro
diagnosis ecosystem, accelerates the cultivation of the in vitro diagnosis market and continuously enhances its brand influence
of LBP. It is committed to becoming a leading enterprise integrating R&D, production, sales, service and education & training of
pathological diagnosis technology in China.
